Compositions for the prophylaxis and treatment of dermatological/mucosal diseases, and uses thereof

a technology for mucosal diseases and compositions, applied in the field of compositions for the prophylaxis and treatment of dermatological/mucosal diseases/disorders, can solve the problems of unfavorable skin-neutral value, unfavorable skin-neutral value, and low ph of medical formulations, so as to improve the function of epidermal/mucosal barrier, improve fibroblast proliferation, and improve the effect of x

Inactive Publication Date: 2011-09-08
DESPHARMA
View PDF5 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0031]We have surprisingly found that a composition that is able to form an electric double layer in aqueous or non-aqueous medium, and shows a stable negative charge, has a cation exchange capacity and cation binding capacity, furthermore contains total magnesium ions more than the total amount of calcium ions, in combination with a non-ionic, anionic, amphoteric or very weakly cationic carrier, is able to recover damaged epidermal barrier upon topical application on the affected skin area.
[0032]A negative charge can be formed by any natural or artificial clay material with a negative surface charge. Zeolites, especially clinoptilolite are the preferred choice of clay material according to the present invention. The clay material is preferably in the form of small particles (micronized particles), since this average size range provides acceptable small particles to be applicable on skin surface, and acceptable high specific surface and charge. According to the present invention the minimal average clay particle size is 5 nm, —the applied particle size depends on the surface type and the status of its barrier damage—, which can make sure that the composition does not penetrate through the skin / into the blood stream, therefore can remain on the skin surface for a time period which is necessary for the desired therapeutic effect.
[0034]The presence of calcium ions in the composition of the invention is also necessary. Calcium assists exocytosis of the lamellar granules in stratum granulosum and induces terminal differentiation of stratum corneum, formation of cornified envelope and also epidermal lipid synthesis. After extrusion of lamellar granules content, the applied ionic environment contribute for the stacks of membranes to reorganize structurally, to form patterned lamellar sheets via edge-to-edge fusion of the lipid stacks. Calcium also activates the trans-glutaminase enzyme to irreversibly cross-link the cornefied envelope proteins, creating a tough insoluble sac that surrounds the keratin fibers.
[0036]According to the present invention, the composition should be able to form an electric double layer in aqueous or non-aqueous medium, and should provide a stable negative charge.

Problems solved by technology

The further problem with dolomite is its nickel content, which is undesired in most of said dermatological diseases.
However, the main drawback of these medical formulations is the pH of the formulations that is far from the skin-neutral value (which is about pH 5.5).
The strongly basic or acidic character of these formulations might result in irritation and in slower recovery of the skin diseases to be treated.
Moreover, one can not reproduce these formulations, since the exact Ca:Mg ratio is not clearly defined in the description.
To summarize, the problem with the formulations according to this prior art document is that it either relates to a silicium dioxide carrier with calcium carbonate and magnesium carbonate, however, the pH of these formulations is undesired, or zeolite is mentioned together with dolomit, however, here the calcium to magnesium ratio is not defined.
Although the agent according to this state of the art document comprises calcium and / or magnesium ions, the drawback of this formulation is that it does not necessarily contain both of them.
Although the role of the epidermal barrier was recognized in several skin diseases / disorders, according to the state of the art there is no pharmaceutical / cosmetic composition available that were optimized to the finding according to which these skin diseases could be treated by epidermal skin barrier formation and / or recovery.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

example 1a

Cream Formulation for the Treatment of Atopic Dermatitis

[0061]A cream was formulated for the treatment of atopic dermatitis, where said cream consisted of the following ingredients (INCI (International Nomenclature of Cosmetic Ingredients) names of the ingredients are provided):

Ingredientm / m %Aqua57.600White petrolatum17.153Cetearyl alcohol10.292Paraffin3.430Polysorbate 603.430Clinoptilolite*3.439Glycerine2.579Alcohol1.543Magnesium chloride0.214Methylparaben0.171Phospholipid0.133Sphyngolipid0.016*contains calcium

example 1b

Zeta Potential Measurement

[0062]Zeta potential of the cream according to Example 1a was measured. Measurement was performed by Brookhaven ZetaPALS instrument in the presence of 1 mM MgCl2 inert electrolyte at 30° C. The instrument is equipped with Peltier element for the active temperature control. The ZetaPALS determines zeta potential using Phase Analysis Light Scattering method based on the shifted frequency spectrum. Palladium electrodes with acrylic supports were used for the measurement.

Results of the Zeta Potential Measurement:

Conductivity: 566 pS

[0063]Electroforetic mobility: −0.87*10−8 m2 / Vs

Zeta potential (calculated by Smoluchowsky theory): −10.02 mV

Zeta potential (calculated by Hiickel theory): −15.04 mV

[0064]Accordingly, zeta potential of the composition is within the required negative range.

example 1c

Electric Surface Potential Measurements

[0065]Electric surface potential measurements were carried out with the cream of Example 1a on intact skin surfaces of human volunteers.

Measurement Conditions:

[0066]Machine: Consort C831 electrochemical analysator[0067]Electrodes: EKG adhesive electrodes[0068]Connecting medium: REXTRA EKG, EEG, EMG diagnostic gel for medical use, pH 6.5[0069]Ingredients: Aqua, Carbomer, Triethanolamine, Methylchloroisothiazolinone, methylisothiazolinone[0070]Measured data row: 25 points, 10 sec / point[0071]Place of measurements: lower arm flexor area in inactive position[0072]Cream applied on: a 5×5 cm surface, after 15 minutes cream removed[0073]Distance of the electrodes: 10 cm[0074]Number of volunteers: 3

[0075]Results are shown in the following Table 1.

TABLE 1Results of the electric surface potential measurements of Example 1cMeas.Volunteer 1Volunteer 2Volunteer 3pointsecM1M2resultM1M2resultM1M2result10−65−122−5720−86−10633−98−131210−60−127−6720−90−11041−99−1...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention provides a composition containing a) clay material with a negative surface charge; b) magnesium ions and calcium ions both either incorporated within the clay material and / or added separately; c) water and / or non-aqueous solvent; d) substantially non-cationic carrier; where i) the mean particle size of the clay material is at least 5 nm; and ii) the total molar amount of magnesium ions is higher than the total molar amount of calcium ions. The present invention further relates to the use of said composition in the manufacture of a medicament for the prophylaxis and treatment of skin diseases, skin conditions, or mucosal diseases where the formation and / or recovery of epidermal / mucosal barrier function has beneficial effects.

Description

FIELD OF THE INVENTION[0001]The present invention relates to compositions for the prophylaxis and treatment of dermatological and mucosal diseases / disorders. In particular, the present invention relates to novel compositions for the prophylaxis and treatment of dermatological diseases / disorders, skin conditions, and mucosal diseases / disorders where epidermal / mucosal barrier formation and / or recovery would have beneficial effects. The invention further relates to the use of such compositions in the manufacture of medicaments / medical devices / care products for the prophylaxis and treatment of said diseases.BACKGROUND OF THE INVENTION[0002]The outermost layer of the skin is the epidermis and the mucosal membranes (e.g. buccal, nasal, intestinal, anal) which forms a barrier between the body and the external environment. This semipermeable epidermal barrier prevents both the escape of moisture and the entry of infectious or toxic substances. Common inflammatory skin disorders such as atop...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K33/14A61K9/00A61K9/70A61K8/19A61P1/04A61P17/02A61P17/04A61P17/06
CPCA61K33/06A61K33/12A61K33/14A61K2300/00A61P1/02A61P1/04A61P11/02A61P11/04A61P17/00A61P17/02A61P17/04A61P17/06A61P37/08A61K9/0014A61K9/14
Inventor FELEKI, ATTILAMIGO, THEODORUS A.C.
Owner DESPHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products